GLP-1 analog fusion proteins

The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions...

Full description

Saved in:
Bibliographic Details
Main Authors Glaesner, Wolfgang, Millican, Jr, Rohn Lee, Vick, Andrew Mark
Format Patent
LanguageEnglish
Published 25.09.2012
Online AccessGet full text

Cover

More Information
Summary:The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.